 
 
 
  
Corporate Office: 
Solara Active Pharma Sciences Limited 
TICEL Bio Park, 6th Floor,             
Module No. 601, 602, 603, Phase II – CSIR Road,  
Taramani, Chennai, Tamil Nadu – 600113.  
Tel: +91 44 4344 6700 
Fax: +91 44 47406190 
E-mail: investors@solara.co.in 
website: www.solara.co.in 
 
 
Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 
Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91-22-20870033 
November 19, 2025  
 
The BSE Limited 
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001 
The National Stock Exchange of India Limited 
Exchange Plaza, C-1, Block G, Bandra-Kurla 
Complex, Bandra (E), Mumbai – 400 051 
 
Scrip Code: 541540, 890202         Scrip Code: SOLARA, SOLARAPP1 
 
Dear Sir/ Madam,  
 
Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure           
Requirements) Regulation, 2015 
 
We are enclosing herewith a press release issued by the Company titled hereunder, with respect 
to the EIR (Establishment Inspection Report ) received from US FDA for the inspection 
completed and classified as VAI (Voluntary Action Indicated).  
 
“Solara is pleased to announ ce the successful closure of US FDA inspection of its 
Mangalore Facility with continued state of compliance on cGMP” 
 
 
Thanking you,  
 
Yours Faithfully,  
For Solara Active Pharma Sciences Limited 
 
 
 
Pooja Jaya Kumar 
Company Secretary and Compliance Officer 
Membership No: A57415 
 
PRESS RELEASE  
WWW.SOLARA.CO.IN | BSE:541540; 890202 | NSE: SOLARA; SOLARAPP1 | BLOOMBERG: SOLARA: IN | SECTOR: PHARMACEUTICALS 
Solara is pleased to announce the successful closure of US FDA inspection of 
its Mangalore Facility with continued state of compliance on cGMP 
Chennai, India – Nov 19, 2025: Solara Active Pharma Sciences Limited (Solara), a leading pure play Active 
Pharmaceutical Ingredient provider is pleased to announ ce that its multi-product manufacturing facility at 
Mangalore, Kar nataka has successfully completed the inspection carried out by the US Food and Drug 
Administration (US FDA) between 25 th to 29 th Aug 2025. The Agency has issued an EIR (Establishment 
Inspection Report) on 18 th Nov 2025 and determined that the inspection classification of the facility is 
“Voluntary Action Indicated (VAI)” and concluded this inspection as closed. 
Solara continues to stay focused on maintaining the highest level of complianc e across its manufacturing 
facilities.  
Commenting on the Inspection Outcome, Sandeep Rao, MD & CEO said “We have successfully 
completed the FDA inspection at our Mangalore facility between 25 th to 29 th Aug 2025. At the end of the 
inspection, two Form FDA 483 inspectional observations were issued by the investigator. The observations 
were procedural in nature. We had submitted our formal response to FDA well within the timeline set by 
the Agency and the Agency has issued an EIR and concluded that the inspection is closed. The inspection 
outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and 
relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.” 
The Mangalore multi-product API manufacturing facility is well equipped with appropriate infrastructure to 
include several independent production blocks and related packaging sections. This site is inspected by various 
Regulatory Authorities including US FDA, EDQM, HPRA, TGA, WHO, PMDA, and MFDS, Korea.   
About Solara 
Solara Active Pharma Sciences Lt d (BSE-541540; 890202, NSE- SOLARA; SOLARAPP1) is a pure play 
global API manufacturer supported by state-of-the-art R&D and ma nufacturing facilities. With 6 
manufacturing facilities and an R&D Centre, Solara offers a basket of diversified, high-value Commercial 
APIs and Contract manufacturing services. Its API facilities are approved by various international regulatory 
agencies including the USFDA, EDQM, MFDS, WHO, PMDA etc. 
Investor / Analyst contact          Statutory and corporate affairs 
Abhishek Singhal   
 abhishek.singhal@solara.co.in   
 +91 99877 66968 
Pooja Jaya Kumar 
Raghavan. V  
 investors@solara.co.in 
Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government 
actions, local, political, or economic developments, technologica l risks, and many other factors that could cause actual result s to differ materially from those c ontemplated by the relevant forward-
looking statements. Solara Active Pharma Sciences Ltd will not be in any way res ponsible for any action taken based on such sta tements and undertakes no obligation to publicly update these forward-
looking statements to reflect subsequent events or circumstances. 
